FDA warns Pfizer's arthritis, colitis drug raises risk of heart issues and cancer
The Food and Drug Administration (FDA) on Thursday warned that early results from a safety trial on Pfizer’s arthritis and colitis drug, tofacitinib, revealed an increased risk of heart issues and cancer when compared to another medicine. The drug, marketed under Xeljanz or Xeljanz XR, was tested against an arthritis drug called tumor necrosis factor (TNF)…